Catalyst Depreciation And Amortization from 2010 to 2024

CPRX Stock  USD 15.92  0.22  1.36%   
Catalyst Pharmaceuticals Depreciation And Amortization yearly trend continues to be fairly stable with very little volatility. Depreciation And Amortization is likely to outpace its year average in 2024. Depreciation And Amortization is the systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives. View All Fundamentals
 
Depreciation And Amortization  
First Reported
2006-09-30
Previous Quarter
9.1 M
Current Value
9.4 M
Quarterly Volatility
2.2 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Catalyst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Catalyst main balance sheet or income statement drivers, such as Interest Expense of 5 M, Other Operating Expenses of 327 M or Operating Income of 91.2 M, as well as many exotic indicators such as Price To Sales Ratio of 4.26, Dividend Yield of 0.0 or PTB Ratio of 4.38. Catalyst financial statements analysis is a perfect complement when working with Catalyst Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement Catalyst Pharmaceuticals' financial leverage analysis and stock options assessment as well as various Catalyst Pharmaceuticals Technical models . Check out the analysis of Catalyst Pharmaceuticals Correlation against competitors.
For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.

Latest Catalyst Pharmaceuticals' Depreciation And Amortization Growth Pattern

Below is the plot of the Depreciation And Amortization of Catalyst Pharmaceuticals over the last few years. It is the systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives. Catalyst Pharmaceuticals' Depreciation And Amortization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Catalyst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Depreciation And Amortization10 Years Trend
Slightly volatile
   Depreciation And Amortization   
       Timeline  

Catalyst Depreciation And Amortization Regression Statistics

Arithmetic Mean4,721,459
Geometric Mean121,752
Coefficient Of Variation251.73
Mean Deviation7,800,031
Median43,406
Standard Deviation11,885,106
Sample Variance141.3T
Range34.8M
R-Value0.61
Mean Square Error96T
R-Squared0.37
Significance0.02
Slope1,614,698
Total Sum of Squares1977.6T

Catalyst Depreciation And Amortization History

202434.8 M
202333.1 M
20221.2 M
2021192 K
2020885.3 K
2019297.7 K
201838 K

About Catalyst Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Catalyst Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Catalyst Pharmaceuticals investors use historical funamental indicators, such as Catalyst Pharmaceuticals's Depreciation And Amortization, to determine how well the company is positioned to perform in the future. Although Catalyst Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Catalyst Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Catalyst Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Catalyst Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Catalyst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Depreciation And Amortization33.1 M34.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Catalyst Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Catalyst Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Catalyst Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Catalyst Pharmaceuticals Stock:
Check out the analysis of Catalyst Pharmaceuticals Correlation against competitors.
For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for Catalyst Stock analysis

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Is Catalyst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalyst Pharmaceuticals. If investors know Catalyst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalyst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.27)
Earnings Share
0.56
Revenue Per Share
3.771
Quarterly Revenue Growth
0.154
Return On Assets
0.0929
The market value of Catalyst Pharmaceuticals is measured differently than its book value, which is the value of Catalyst that is recorded on the company's balance sheet. Investors also form their own opinion of Catalyst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Catalyst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalyst Pharmaceuticals' market value can be influenced by many factors that don't directly affect Catalyst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalyst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalyst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalyst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.